"Because of the projected aging of the human population, the burden from diseases of aging is expected to increase dramatically over the next 20-25 years. The identification of a putative common molecular mechanism influencing these diseases and amenable of a therapeutic modulation would result not only in an improvement of the quality of life for this segment of the population but also in a significantly reduced socio-economic impact of these diseases. The fact that the 5-LO is significantly increased with aging, which associates with the development of cardiovascular as well as neurodegenerative diseases, makes this enzymatic pathway an excellent candidate that fulfills these criteria." (Chu, 2009)
5-Lipoxygenase (5-LO, 5-LOX) is an enzyme which oxidizes polyunsaturated fatty acids and converts them to pro-inflammatory molecules known as leukotrienes. Specifically the 5-LOX enzyme has been tied to the production of leukotrienes LTA4, LTB4, and LTC4. 5-LOX activity increases with aging, and studies have associated this enzyme's activity with various diseases for which aging is an increasing risk factor including arthritis, cardiovascular disease, and neurodegenerative disease.
The Boswellia serrata extract is the first selective, direct, non-competitive and non-redox-type inhibitor of 5-lipoxygenase, the key enzyme for leukotriene biosynthesis. Experimental and clinical usage of Boswellia indicates it has none of the side-effects on blood pressure, heart rate, or the gastric irritation and ulcers associated with many anti-inflammatory and anti-arthritic drugs. (Legere, 2018)
Read more about 5-LOX at http://legerepharm.com/uploads/DietaryInflammation.pdf
Chu, J. & Pratico, D. (2009). The 5-Lipoxygenase as a Common Pathway for Pathological Brain and Vascular Aging. Cardiovascular Psychiatry and Neurology. Vol. 2009.
Legere, J. & Legere, R. (2018). Dietary Sources of Inflammation. Legere Pharmaceuticals. Retrieved from: http://legerepharm.com/uploads/DietaryInflammation.pdf